Raghad Abdul-Karim, MD
Hematology & Oncology · McAllen, TXNPI 1114207172
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.1%), food and beverage and education — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Eisai Inc. at 59.1% of the total. 2025 is the largest year on record at $2,308, 5.0 times the $463 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 56 payments — averaging $61.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$2K
- AstraZeneca$165
- Amgen$129
- Pfizer$128
- Cardinal Health 108 LLC$111
- Bayer$105
- plus $776 from 24 others
Across 114 payments — averaging $9839.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$363K
- Pfizer$198K
- Takeda Pharmaceuticals U.S.A., Inc.$188K
- Gilead$145K
- Synthorx Inc.$77K
- Modernatx, Inc.$38K
- plus $114K from 7 others
What the payments were for
- Consulting fees$1,94056%
- Food & beverage$1,50543%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 2 | $2,045 |
| AstraZeneca(2 entities) | 6 | $165 |
| Amgen | 1 | $129 |
| Pfizer | 6 | $128 |
| Cardinal Health 108 LLC | 2 | $111 |
| Bayer | 7 | $105 |
| Acera Surgical, Inc. | 1 | $98 |
| Seagen Inc. | 2 | $77 |
| Avyxa Pharma, LLC | 1 | $66 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $56 |
| Johnson & Johnson | 2 | $51 |
| Siemens Medical Solutions USA, Inc. | 1 | $51 |
| Daiichi Sankyo Inc. | 3 | $50 |
| Merck | 2 | $35 |
| Tesaro, Inc. | 1 | $34 |
| Puma Biotechnology, Inc. | 2 | $33 |
| Novartis | 1 | $24 |
| Gilead | 1 | $23 |
| Incyte Corporation | 1 | $22 |
| Lilly USA, LLC | 1 | $19 |
| AbbVie | 1 | $18 |
| Bristol Myers Squibb | 1 | $16 |
| AVEO Pharmaceuticals, Inc. | 1 | $15 |
| Exelixis Inc. | 1 | $14 |
| Blueprint Medicines Corporation | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Sanofi | 1 | $13 |
| Boehringer Ingelheim | 1 | $12 |
| Tactile Systems Technology Inc | 1 | $11 |
| Genentech USA, Inc. | 1 | $11 |
How this compares
$3,460 in reported general payments places this provider in the 50th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 36 | $577,061 |
| TagrissoOsimertinib Mesylate | 29 | $465,893 |
| LynparzaOlaparib | 12 | $122,040 |
| EliquisApixaban | 54 | $47,133 |
| Abiraterone Acetate | 12 | $38,717 |
| Ondansetron Hcl | 123 | $2,557 |
| Letrozole | 112 | $2,415 |
| Prochlorperazine Maleate | 120 | $2,056 |
| Dexamethasone | 69 | $1,849 |
| Anastrozole | 33 | $1,777 |
| Enoxaparin Sodium | 12 | $1,570 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 23 | $904 |
| Potassium Chloride | 12 | $832 |
| LoperamideLoperamide Hcl | 21 | $765 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 28 | $522 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Lynparza | $165 | $587,93341 claims |
| Lilly USA, LLCVerzenio | $19 | $577,06136 claims |
| PfizerEliquis | $128 | $47,13354 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in McAllen
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
- Timothy FenskeSan Antonio$626K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.